FDA allows Actavis to market generic Aricept in US
The US Food and Drug Administration (FDA) has given marketing approval to Actavis' Donepezil Hydrochloride Tablets, a generic equivalent of Aricept, in the US.
Aricept (donepezil HCl) is a prescription medicine to treat mild, moderate and severe Alzheimer's disease.
Actavis is a pharmaceutical company specializing in the development, manufacture and sale of generic pharmaceuticals.
Based in Morristown, NJ, Actavis has operations in 40 countries, with more than 10,500 employees.
Related Insight
Suppliers Directory
Metris - Animal Behaviour Analysis Solutions
Metris B.V. is a trendsetter in the field of animal behaviour research. The company consistently develops and introduces innovative technologies for preclinical research, by automating behavioural research, ultrasonic vocalisation analysis and sleep research. Metris products are internationally marketed and supported by experienced staff of sales and service engineers.
Regulatory Affairs > Suppliers
David Begg Associates - Pharmaceutical Training, Consultancy and Auditing
Since its foundation in 1986, David Begg Associates (DBA) has risen to become Europe's largest provider of pharmaceutical education and training with an outstanding international reputationin the fields of pharmaceutical quality management and regulatory compliance. DBA now brings that reputation to the US, complementing its EU expertise with experts in FDA and other markets to offer education and training programs, consultancy and auditing services.
Regulatory Affairs > Suppliers
SHL Group - Designer, Developer & Supplier of Auto Injectors & Pen Injectors
SHL (Scandinavian Health Ltd.) is the world's largest privately-owned designer, developer and supplier of advanced drug delivery devices.
Regulatory Affairs > Suppliers
LORENZ - Life Sciences Group
LORENZ is the most established provider of e-regulatory software and services in the world. Since 1989, LORENZ has focused exclusively on bringing intuitive, business-driven solutions to the market.
Regulatory Affairs > Suppliers
Production & Manufacturing
Fine & Speciality Chemicals
Manufacturing
Process & Production
OTC
Drug Research Drug Delivery Drug Discovery & Development
Contract Research & Services Clinical Trials Contract Research Contract Services
Automation IT & Software Laboratory Instrumentation
Inward Investment Packaging Regulatory Affairs
Drug Research Drug Delivery Drug Discovery & Development
Contract Research & Services Clinical Trials Contract Research Contract Services
Automation IT & Software Laboratory Instrumentation
Inward Investment Packaging Regulatory Affairs
Regulatory Affairs Intelligence
The Future of Glass as Parenteral Primary Packaging: Issues and Challenges
Published by Parenteral Drug Association (PDA)
Regulatory Affairs > White Papers
Laboras: Automated Behavior Recognition and Motion Tracking
Published by Metris
Regulatory Affairs > White Papers
Efficient Pharmacovigilance Process Based on Document Management
Published by Infotehna Group
Regulatory Affairs > White Papers
Buy the latest industry research online today!
Nanotechnology in Drug Delivery - Technological Improvements and Novel Approaches to Fulfill High Potential
GBI Research, the leading business intelligence provider, has released its latest report, “Nanotechnology in Drug Delivery - Technological Improvements and Novel Approaches to Fulfill High Potential” that provides key data, information and analysis of the major trends and issues affecting the global nano-enabled drug delivery market. The report provides a comprehensive insight into the current and future application of nanotechnology in the drug delivery systems. It also provides an insight into the key drivers and barriers for the market growth. The report also provides a detailed analysis of the trends and its effects on the nano-enabled drug delivery market. The report also talks about the key regulations that affect the nanotechnology research and development and issues related to its use in pharmaceutical market. The report also details some case study of the latest technology being exploited in pharmaceutical industry. The report also provides detailed analysis of major deals that have happened in the nano-enabled drug delivery market landscape. At the end, the report looks into the future players. This report is built using data and information sourced from proprietary databases, primary and secondary research and in house analysis by GBI Research’s team of industry experts. The nano-enabled drug delivery market has been a high growth market and expected to grow at a faster rate in the near future. According to a study conducted by Willi Paul, and Chandra P. Sharma, the nano-enabled drug delivery market was $1.7 billion in 2009 and expected to reach over $4.8 billion in 2012. The market will witness increased competition, high investment from venture capitalist and government. The M&A and Licensing landscape will see significant changes in the coming future. This is because market is expected to become more lucrative in coming future. The major drivers for the market growth are Increasing acceptance of nano-enabled drugs, and a strong pipeline portfolio. The increasing governmental funding and R&D interest will strengthen the market in future. However, lack of consistent policy on technology transfer, poor R&D facility, and tight audit control and lack of centralized system will restrain the market growth. The nano-enabled drug delivery market has strong pipeline. The pipeline is primarily dominated by molecules in early stage of development. This suggests that the there is high level of R&D investment. This will support the future market and will fuel the licensing activity. Buy online from $3500
GBI Research, the leading business intelligence provider, has released its latest report, “Nanotechnology in Drug Delivery - Technological Improvements and Novel Approaches to Fulfill High Potential” that provides key data, information and analysis of the major trends and issues affecting the global nano-enabled drug delivery market. The report provides a comprehensive insight into the current and future application of nanotechnology in the drug delivery systems. It also provides an insight into the key drivers and barriers for the market growth. The report also provides a detailed analysis of the trends and its effects on the nano-enabled drug delivery market. The report also talks about the key regulations that affect the nanotechnology research and development and issues related to its use in pharmaceutical market. The report also details some case study of the latest technology being exploited in pharmaceutical industry. The report also provides detailed analysis of major deals that have happened in the nano-enabled drug delivery market landscape. At the end, the report looks into the future players. This report is built using data and information sourced from proprietary databases, primary and secondary research and in house analysis by GBI Research’s team of industry experts. The nano-enabled drug delivery market has been a high growth market and expected to grow at a faster rate in the near future. According to a study conducted by Willi Paul, and Chandra P. Sharma, the nano-enabled drug delivery market was $1.7 billion in 2009 and expected to reach over $4.8 billion in 2012. The market will witness increased competition, high investment from venture capitalist and government. The M&A and Licensing landscape will see significant changes in the coming future. This is because market is expected to become more lucrative in coming future. The major drivers for the market growth are Increasing acceptance of nano-enabled drugs, and a strong pipeline portfolio. The increasing governmental funding and R&D interest will strengthen the market in future. However, lack of consistent policy on technology transfer, poor R&D facility, and tight audit control and lack of centralized system will restrain the market growth. The nano-enabled drug delivery market has strong pipeline. The pipeline is primarily dominated by molecules in early stage of development. This suggests that the there is high level of R&D investment. This will support the future market and will fuel the licensing activity. Buy online from $3500
Comments may be moderated for spam, obscenities or defamation.